NCT07063706Completed
Pharmaceutical Care for Patients Using Capecitabine
Impact of Pharmaceutical Care on Patients Using Capecitabine: a Multicenter Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 18 Jul 2025
Brief summary (registry, in English)
This is a longitudinal, prospective and intervention study, which will be carried out with patients undergoing treatment with capecitabine, where the impact of pharmaceutical care will be evaluated.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 176 (actual)
- First submitted
- 25 Jun 2025
- Start date
- 1 Mar 2022
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- Faculdade de Farmácia
- Diseases
- Colorectal cancer
- NCT number
- NCT07063706
What you commit to
- Study type: Interventional
- Participants enrolled: 176
- From 1 Mar 2022 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously started capecitabine treatment, with more than one full cycle completed prior to enrollment.
Other illness
- Any clinical condition that, in the investigator's judgment, may compromise full participation in the study.
Other
- Inability to communicate verbally or significant difficulty in understanding that prevents adherence to pharmaceutical care instructions.
- Refusal or inability to sign the Informed Consent Form.
- Participation in another clinical study that may interfere with outcomes related to pharmaceutical care.
Who the study is looking for
- Patients initiating treatment with capecitabine, either: as monotherapy, or in combination with other antineoplastic therapies and/or radiotherapy.
- No restrictions regarding therapeutic regimen or disease stage.
- Age 18 years or older.
- Patients being followed at one or both of the following institutions: Hospital do Câncer I of the National Cancer Institute (INCA), and/or Clementino Fraga Filho University Hospital (UFRJ).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Nacional de Câncer Coordinator of this site? Confirm its status | Rio de Janeiro | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.